Shares of other companies:
April 24, 2024 Google’s Third Cookie Phaseout Delay Amid Regulatory Hurdles
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
Tesla Is An AI Company That The Market Won’t Reward For Now
April 24, 2024
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
ACAD Stock News and Mentions of ACADIA Pharmaceuticals Inc. Stocktwits
Updated: April 26, 2024 (09:55)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where ACADIA Pharmaceuticals Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of ACADIA Pharmaceuticals Inc. (ACAD).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the ACADIA Pharmaceuticals stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of ACADIA Pharmaceuticals Inc. (ACAD)
April 12, 2024 (10:12) / "Stocknews.com" (by StockNews.com Staff)
ALPMY: 3 Affordable Pharma Stocks to Buy for Portfolio Gains
The pharmaceutical industry is undergoing a transformative boom, leveraging digital platforms, big data analytics, cloud computing, and AI to drive innovation. Moreover, the growing demand for personalized drugs and increased R&D activities should give an additional boost to the already ...
In Article Trend: Somewhat-Bullish
April 1, 2024 (11:54) / "Business Insider" (by PRESS RELEASE ACCESSWIRE)
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA ... - Markets Insider ...
In Article Trend: Neutral
March 28, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
Why Is Acadia ( ACAD ) Down 23.4% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 27, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
Stoke Therapeutics ( STOK ) Up on Upbeat Dravet Syndrome Study Data
Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.
In Article Trend: Neutral
March 14, 2024 (16:07) / "Zacks Commentary" (by Zacks Equity Research)
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.
In Article Trend: Neutral
March 12, 2024 (16:04) / "Benzinga" (by Akanksha Bakshi)
Bitcoin, Ethereum, Dogecoin Surge, Crypto Market Cap Hits $2.5T While MicroStrategy Loads Up On BTC; Tesla's German Factory Back Online After Arson Attack Disrupts Production - Top Headlines Today While US Slept
'BONK Killer' MILLI Skyrockets 20% In A Day, Outperforming Dogecoin, Shiba Inu: Targets $15M Market Cap Within Week Of Its Launch Staggering $47M Stolen In Crypto By Bitcoin, Dogecoin And Shiba Inu Phishers In February, Targeting 57K Victims On Elon Musk's X
In Article Trend: Somewhat-Bearish
March 12, 2024 (15:06) / "Zacks Commentary" (by Zacks Equity Research)
Acadia ( ACAD ) Down as Schizophrenia Study on Nuplazid Fails
Acadia (ACAD) tumbles after its late-stage study on pimavanserin to treat negative symptoms of schizophrenia fails to achieve the primary goal with statistical significance.
In Article Trend: Neutral
March 12, 2024 (13:17) / "Benzinga" (by Avi Kapoor)
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday - Oracle ( NYSE:ORCL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Oppenheimer cut the price target for ACADIA Pharmaceuticals Inc. ACAD from $25 to $19.
In Article Trend: Somewhat-Bullish
March 12, 2024 (13:12) / "Investors Business Daily" (by ALLISON GATLIN)
Acadia Plummets After Placebo Effect Torpedoes Schizophrenia Study
Acadia stock crashed to an 11-month low Tuesday after an outsized placebo effect torpedoed the company's efforts to expand Nuplazid to schizophrenia patients. Acadia Pharmaceuticals ( ACAD ) had been hoping its antipsychotic, Nuplazid, would make a difference for people with the negative symptoms ...
In Article Trend: Neutral
March 12, 2024 (12:11) / "Benzinga" (by Avi Kapoor)
Why Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Oracle ( NYSE:ORCL )
Shares of Oracle Corporation ORCL rose sharply in today's pre-market trading after the company reported upbeat earnings for its fiscal third quarter. Oracle's third-quarter revenue increased 7% year-over-year to $13.3 billion, which missed the consensus estimate of $13.306 billion, according to ...
In Article Trend: Somewhat-Bullish
March 12, 2024 (11:19) / "Benzinga" (by Vandana Singh)
Why Is Acadia Pharmaceuticals Stock Trading Lower On Tuesday? - ACADIA Pharmaceuticals ( NASDAQ:ACAD )
Monday, Acadia Pharmaceuticals Inc ACAD released top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for negative symptoms of schizophrenia.
In Article Trend: Neutral
March 12, 2024 (09:36) / "Benzinga" (by Avi Kapoor)
ACADIA Pharmaceuticals, Ocular Therapeutix, Asana And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - ACADIA Pharmaceuticals ( NASDAQ:ACAD ) , Ocular Therapeutix ( NASDAQ:OCUL )
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining by around 50 points on Tuesday. Shares of ACADIA Pharmaceuticals Inc ACAD fell sharply in today's pre-market trading after the company reported the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of ...
In Article Trend: Neutral
March 7, 2024 (21:07) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD - ACADIA Pharmaceuticals ( NASDAQ:ACAD )
NEW YORK, March 07, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ( "ACADIA" or the "Company" ) ACAD. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
In Article Trend: Neutral
March 3, 2024 (15:15) / "PR Newswire" (by Pomerantz LLP)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals ... PR ...
In Article Trend: Neutral
February 28, 2024 (20:10) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD - ACADIA Pharmaceuticals ( NASDAQ:ACAD )
NEW YORK, Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ( "ACADIA" or the "Company" ) ACAD. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
In Article Trend: Neutral
February 28, 2024 (16:16) / "Investors Business Daily" (by Investor's Business Daily)
Biotech Dives As Seasonality Rocks Its Most High-Profile Launch
Acadia Stock Plummets As Seasonality Rocks Its High-Profile Launch Investor's Business Daily ...
In Article Trend: Neutral
February 28, 2024 (14:12) / "Zacks Commentary" (by Zacks Equity Research)
Acadia ( ACAD ) Q4 Earnings Lag, Sales Beat Estimates, Stock Down
Acadia's (ACAD) fourth-quarter earnings miss estimates while revenues beat the same. Higher product sales drive year-over-year revenues. Shares fall in after-hours trading.
In Article Trend: Neutral
February 28, 2024 (13:30) / "GlobeNewswire" (by Inc.)
Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer
BEDFORD, Mass., Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- Lantheus Holdings, Inc. ( "Lantheus" ) ( NASDAQ: LNTH ) , the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the promotion of ...
In Article Trend: Somewhat-Bullish
February 28, 2024 (13:30) / "Benzinga" (by Globe Newswire)
Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer - Lantheus Holdings ( NASDAQ:LNTH )
BEDFORD, Mass., Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- Lantheus Holdings, Inc. ( "Lantheus" ) LNTH, the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the promotion of Amanda Morgan ...
In Article Trend: Somewhat-Bullish
February 28, 2024 (12:00) / "Benzinga" (by Globe Newswire)
AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors
NEW ORLEANS, Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- AxoSim, Inc., a leader in the development and application of 3D organoid neurodiscovery platforms, today announced that current directors Dale Pfost, PhD, and David Weiner, MD, have been appointed as Co-Chairs of AxoSim's Board of Directors.
In Article Trend: Somewhat-Bullish
February 27, 2024 (22:20) / "Zacks Commentary" (by Zacks Equity Research)
Acadia Pharmaceuticals ( ACAD ) Q4 Earnings Lag Estimates
Acadia (ACAD) delivered earnings and revenue surprises of -12.50% and 3.57%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
February 27, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
ACADIA Pharmaceuticals Earns Relative Strength Rating Upgrade
The Relative Strength ( RS ) Rating for ACADIA Pharmaceuticals ( ACAD ) jumped into a new percentile Tuesday, as it got a lift from 61 to 71. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website